Skip to main contentSkip to navigationSkip to search
Curasight

Curasight - Providing answers for cancer patients

Curasight technology

Play video

Latest Press Releases

Results from Phase II study in prostate cancer to be published in the Journal of Nuclear Medicine

December 21, 2020
 | Regulatory

Japanese patent application 2019-005811 is accepted for grant

December 16, 2020
 | Regulatory

Financial Calendar 2021

December 15, 2020
 | Regulatory

Company

Curasight is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and treatment in multiple cancer types, most notably for brain and prostate cancer. 

Technology

Curasight builds its novel uPAR-PET imaging approach on a deep understanding of the uPAR system and it’s role in cancer, together with extensive experience with translational molecular imaging, which has been obtained through more than a decade of research at Rigshospitalet and University of Copenhagen

Pipeline

Curasight is focused on addressing the need for improved diagnosis and treatment of brain and prostate cancer. Curasight build on its foundation of pioneering research and development within uPAR-PET Imaging. Our clinical development efforts include a program to develop a first-in-class uPAR-PET imaging ligand which is currently in phase II clinical testing

Laboratory equipment

What is Molecular Nuclear Imaging?

Uses trace amount of radioactive substances called radiopharmaceuticals to reveal specific biochemical processes.

Read more about Nuclear Medicine